{"dataset":"Peptides.info claims","version":"2026-10-03","generated":"2026-10-03","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"citation":"Twenty Residues. Peptides.info evidence dataset, version 2026-10-03. https://peptides.info/data. Licensed CC BY 4.0.","methodology":"https://peptides.info/methodology","rows":75,"data":[{"peptide":"semaglutide","peptide_name":"Semaglutide","claim":"Produced ~14.9% mean body-weight loss vs ~2.4% on placebo over 68 weeks in adults with obesity (STEP 1).","tier":1,"kind":"efficacy","source_label":"Wilding et al., 2021 (NEJM, STEP 1)","source_url":"https://pubmed.ncbi.nlm.nih.gov/33567185/","updated":"2026-09-19","page":"https://peptides.info/peptides/semaglutide"},{"peptide":"semaglutide","peptide_name":"Semaglutide","claim":"Cut major adverse cardiovascular events by ~20% in patients with cardiovascular disease and obesity but not diabetes (SELECT).","tier":1,"kind":"efficacy","source_label":"Lincoff et al., 2023 (NEJM, SELECT)","source_url":"https://pubmed.ncbi.nlm.nih.gov/37952131/","updated":"2026-09-19","page":"https://peptides.info/peptides/semaglutide"},{"peptide":"tirzepatide","peptide_name":"Tirzepatide","claim":"Produced ~20.9% mean body-weight reduction at 72 weeks on the top dose vs ~3.1% on placebo (SURMOUNT-1).","tier":1,"kind":"efficacy","source_label":"Jastreboff et al., 2022 (NEJM, SURMOUNT-1)","source_url":"https://pubmed.ncbi.nlm.nih.gov/35658024/","updated":"2026-09-19","page":"https://peptides.info/peptides/tirzepatide"},{"peptide":"tirzepatide","peptide_name":"Tirzepatide","claim":"FDA-approved for type 2 diabetes, chronic weight management, and obstructive sleep apnea in obesity.","tier":1,"kind":"regulatory","source_label":"FDA label – Zepbound (accessdata)","source_url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf","updated":"2026-09-19","page":"https://peptides.info/peptides/tirzepatide"},{"peptide":"retatrutide","peptide_name":"Retatrutide","claim":"83% of participants lost ≥15% body weight and mean loss reached ~24.2% at 48 weeks on the top dose in a Phase 2 RCT.","tier":2,"kind":"efficacy","source_label":"Jastreboff et al., 2023 (NEJM, Phase 2)","source_url":"https://pubmed.ncbi.nlm.nih.gov/37366315/","updated":"2026-09-19","page":"https://peptides.info/peptides/retatrutide"},{"peptide":"retatrutide","peptide_name":"Retatrutide","claim":"Triple agonism at the GLP-1, GIP, and glucagon receptors distinguishes it mechanistically from dual agonists.","tier":3,"kind":"efficacy","source_label":"Structural insights into retatrutide (PMC)","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11255275/","updated":"2026-09-19","page":"https://peptides.info/peptides/retatrutide"},{"peptide":"retatrutide","peptide_name":"Retatrutide","claim":"No approved indication as of 2026; Phase 3 complete, filing planned for Q1 2027.","tier":1,"kind":"regulatory","source_label":"ClinicalTrials.gov – TRIUMPH-1 (NCT05929066)","source_url":"https://clinicaltrials.gov/study/NCT05929066","updated":"2026-09-19","page":"https://peptides.info/peptides/retatrutide"},{"peptide":"aod-9604","peptide_name":"AOD-9604","claim":"Stimulated lipolysis and inhibited lipogenesis in preclinical models without affecting IGF-1 or blood glucose.","tier":3,"kind":"efficacy","source_label":"Ng et al., 2000 (Horm Res)","source_url":"https://pubmed.ncbi.nlm.nih.gov/11146367/","updated":"2026-10-01","page":"https://peptides.info/peptides/aod-9604"},{"peptide":"aod-9604","peptide_name":"AOD-9604","claim":"Did not produce statistically significant weight loss versus placebo in human obesity trials.","tier":2,"kind":"efficacy","source_label":"AOD-9604 Metabolic – review (PubMed)","source_url":"https://pubmed.ncbi.nlm.nih.gov/15134286/","updated":"2026-10-01","page":"https://peptides.info/peptides/aod-9604"},{"peptide":"tesamorelin","peptide_name":"Tesamorelin","claim":"FDA-approved to reduce visceral adipose tissue in HIV-associated lipodystrophy, based on two Phase 3 randomized trials.","tier":1,"kind":"efficacy","source_label":"FDA label – Egrifta SV (accessdata)","source_url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022505s012s013lbl.pdf","updated":"2026-09-19","page":"https://peptides.info/peptides/tesamorelin"},{"peptide":"tesamorelin","peptide_name":"Tesamorelin","claim":"Visceral-fat reduction reverses after discontinuation, so benefit depends on continued use.","tier":1,"kind":"efficacy","source_label":"FDA label – Egrifta SV (accessdata)","source_url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022505s012s013lbl.pdf","updated":"2026-09-19","page":"https://peptides.info/peptides/tesamorelin"},{"peptide":"cjc-1295","peptide_name":"CJC-1295","claim":"Raised GH 2–10× (for ≥6 days) and IGF-1 1.5–3× (for 9–11 days) after a single dose in healthy adults; half-life ~6–8 days.","tier":2,"kind":"efficacy","source_label":"Teichman et al., 2006 (J Clin Endocrinol Metab)","source_url":"https://pubmed.ncbi.nlm.nih.gov/16352683/","updated":"2026-10-01","page":"https://peptides.info/peptides/cjc-1295"},{"peptide":"cjc-1295","peptide_name":"CJC-1295","claim":"No approved human indication.","tier":1,"kind":"regulatory","source_label":"Teichman et al., 2006 (J Clin Endocrinol Metab)","source_url":"https://pubmed.ncbi.nlm.nih.gov/16352683/","updated":"2026-10-01","page":"https://peptides.info/peptides/cjc-1295"},{"peptide":"ipamorelin","peptide_name":"Ipamorelin","claim":"Selective GH release with little effect on ACTH, cortisol, or prolactin in preclinical models.","tier":3,"kind":"efficacy","source_label":"Raun et al., 1998 (Eur J Endocrinol)","source_url":"https://pubmed.ncbi.nlm.nih.gov/9849822/","updated":"2026-10-01","page":"https://peptides.info/peptides/ipamorelin"},{"peptide":"ipamorelin","peptide_name":"Ipamorelin","claim":"Acts as a ghrelin-receptor (GHS-R1a) agonist – a different mechanism from the GHRH analogs.","tier":3,"kind":"efficacy","source_label":"Raun et al., 1998 (Eur J Endocrinol)","source_url":"https://pubmed.ncbi.nlm.nih.gov/9849822/","updated":"2026-10-01","page":"https://peptides.info/peptides/ipamorelin"},{"peptide":"ipamorelin","peptide_name":"Ipamorelin","claim":"Produced a single, dose-dependent GH pulse in healthy volunteers, with a terminal half-life of about two hours.","tier":2,"kind":"efficacy","source_label":"Gobburu et al., 1999 (Pharm Res)","source_url":"https://pubmed.ncbi.nlm.nih.gov/10496658/","updated":"2026-10-01","page":"https://peptides.info/peptides/ipamorelin"},{"peptide":"ipamorelin","peptide_name":"Ipamorelin","claim":"Did not shorten time to first tolerated meal versus placebo in a Phase 2 trial of postoperative ileus after bowel resection (n=114).","tier":2,"kind":"efficacy","source_label":"Beck et al., 2014 (Int J Colorectal Dis)","source_url":"https://pubmed.ncbi.nlm.nih.gov/25331030/","updated":"2026-10-01","page":"https://peptides.info/peptides/ipamorelin"},{"peptide":"ipamorelin","peptide_name":"Ipamorelin","claim":"No approved human indication; remains investigational.","tier":1,"kind":"regulatory","source_label":"Raun et al., 1998 (Eur J Endocrinol)","source_url":"https://pubmed.ncbi.nlm.nih.gov/9849822/","updated":"2026-10-01","page":"https://peptides.info/peptides/ipamorelin"},{"peptide":"bpc-157","peptide_name":"BPC-157","claim":"Accelerated tendon, muscle, and gut-lining healing in rodent injury models.","tier":3,"kind":"efficacy","source_label":"Chang et al., 2011 (J Appl Physiol) – via PMC","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6271067/","updated":"2026-09-19","page":"https://peptides.info/peptides/bpc-157"},{"peptide":"bpc-157","peptide_name":"BPC-157","claim":"No completed placebo-controlled human efficacy trial; the first Phase 2 RCT is only recently registered.","tier":4,"kind":"efficacy","source_label":"Safety of intravenous BPC-157 in humans (PubMed)","source_url":"https://pubmed.ncbi.nlm.nih.gov/40131143/","updated":"2026-09-19","page":"https://peptides.info/peptides/bpc-157"},{"peptide":"bpc-157","peptide_name":"BPC-157","claim":"No approved human indication in any major regulatory jurisdiction.","tier":1,"kind":"regulatory","source_label":"Safety of intravenous BPC-157 in humans (PubMed)","source_url":"https://pubmed.ncbi.nlm.nih.gov/40131143/","updated":"2026-09-19","page":"https://peptides.info/peptides/bpc-157"},{"peptide":"tb-500","peptide_name":"TB-500","claim":"Full-length thymosin β4 promotes cell migration and angiogenesis in vitro and in animal wound models.","tier":3,"kind":"efficacy","source_label":"Goldstein et al., 2005 (Ann N Y Acad Sci)","source_url":"https://pubmed.ncbi.nlm.nih.gov/16110805/","updated":"2026-10-01","page":"https://peptides.info/peptides/tb-500"},{"peptide":"tb-500","peptide_name":"TB-500","claim":"TB-500 is a synthetic Ac-LKKTETQ fragment of thymosin β4, not the native protein.","tier":1,"kind":"efficacy","source_label":"UniProt – thymosin β4 (P62328)","source_url":"https://www.uniprot.org/uniprotkb/P62328/entry","updated":"2026-10-01","page":"https://peptides.info/peptides/tb-500"},{"peptide":"tb-500","peptide_name":"TB-500","claim":"No human clinical trial has tested the TB-500 fragment itself for recovery or injury.","tier":4,"kind":"efficacy","source_label":"Goldstein et al., 2012 (Expert Opin Biol Ther)","source_url":"https://pubmed.ncbi.nlm.nih.gov/22074294/","updated":"2026-10-01","page":"https://peptides.info/peptides/tb-500"},{"peptide":"ghk-cu","peptide_name":"GHK-Cu","claim":"Upregulates collagen, elastin, and repair/remodeling gene programs across cell and tissue models.","tier":3,"kind":"efficacy","source_label":"Pickart & Margolina, 2018 (review, PMC)","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/","updated":"2026-09-19","page":"https://peptides.info/peptides/ghk-cu"},{"peptide":"ghk-cu","peptide_name":"GHK-Cu","claim":"Topical GHK-Cu improved skin density and reduced fine lines vs vehicle over ~12 weeks in small controlled studies.","tier":2,"kind":"efficacy","source_label":"ClinicalTrials.gov – cosmetic GHK study (NCT03103906)","source_url":"https://clinicaltrials.gov/study/NCT03103906","updated":"2026-09-19","page":"https://peptides.info/peptides/ghk-cu"},{"peptide":"kpv","peptide_name":"KPV","claim":"Reduced colitis in mouse models; taken up via the PepT1 transporter and suppresses NF-κB inflammatory signaling.","tier":3,"kind":"efficacy","source_label":"Dalmasso et al., 2008 (Gastroenterology)","source_url":"https://pubmed.ncbi.nlm.nih.gov/18061177/","updated":"2026-10-01","page":"https://peptides.info/peptides/kpv"},{"peptide":"kpv","peptide_name":"KPV","claim":"Anti-inflammatory activity appears largely independent of melanocortin receptors.","tier":3,"kind":"efficacy","source_label":"Getting et al., 2003 (dissecting α-MSH, PubMed)","source_url":"https://pubmed.ncbi.nlm.nih.gov/12750433/","updated":"2026-10-01","page":"https://peptides.info/peptides/kpv"},{"peptide":"kpv","peptide_name":"KPV","claim":"No human clinical trials have been conducted; all efficacy evidence is preclinical.","tier":4,"kind":"efficacy","source_label":"Brzoska et al., 2008 (Endocr Rev)","source_url":"https://pubmed.ncbi.nlm.nih.gov/18612139/","updated":"2026-10-01","page":"https://peptides.info/peptides/kpv"},{"peptide":"mots-c","peptide_name":"MOTS-c","claim":"Activated AMPK and improved insulin sensitivity, reversing diet-induced obesity in mice.","tier":3,"kind":"efficacy","source_label":"Lee et al., 2015 (Cell Metabolism)","source_url":"https://pubmed.ncbi.nlm.nih.gov/25738459/","updated":"2026-10-01","page":"https://peptides.info/peptides/mots-c"},{"peptide":"mots-c","peptide_name":"MOTS-c","claim":"Plasma MOTS-c levels tracked with insulin sensitivity in lean but not obese people (cross-sectional).","tier":2,"kind":"efficacy","source_label":"Cataldo et al., 2018 (J Investig Med)","source_url":"https://pubmed.ncbi.nlm.nih.gov/29593067/","updated":"2026-10-01","page":"https://peptides.info/peptides/mots-c"},{"peptide":"mots-c","peptide_name":"MOTS-c","claim":"Intermittent treatment begun late in life increased physical capacity in old mice; in humans, exercise raised endogenous MOTS-c in muscle and blood.","tier":3,"kind":"efficacy","source_label":"Reynolds et al., 2021 (Nat Commun)","source_url":"https://pubmed.ncbi.nlm.nih.gov/33473109/","updated":"2026-10-01","page":"https://peptides.info/peptides/mots-c"},{"peptide":"epithalon","peptide_name":"Epithalon","claim":"Induced telomerase (hTERT) activity and telomere elongation in cultured human somatic cells.","tier":3,"kind":"efficacy","source_label":"Khavinson et al., 2003 (Bull Exp Biol Med)","source_url":"https://pubmed.ncbi.nlm.nih.gov/12937682/","updated":"2026-10-01","page":"https://peptides.info/peptides/epithalon"},{"peptide":"epithalon","peptide_name":"Epithalon","claim":"Reported lifespan and age-marker effects in rodents and small Russian cohorts; not independently replicated at scale.","tier":4,"kind":"efficacy","source_label":"Anisimov & Khavinson, 2010 (Biogerontology)","source_url":"https://pubmed.ncbi.nlm.nih.gov/19830585/","updated":"2026-10-01","page":"https://peptides.info/peptides/epithalon"},{"peptide":"selank","peptide_name":"Selank","claim":"Comparable anxiolytic effect to a benzodiazepine, with added anti-asthenic effects, in a small Russian study of generalized anxiety and neurasthenia.","tier":4,"kind":"efficacy","source_label":"Zozulia et al., 2008 (Selank in GAD, PubMed)","source_url":"https://pubmed.ncbi.nlm.nih.gov/18454096/","updated":"2026-10-01","page":"https://peptides.info/peptides/selank"},{"peptide":"selank","peptide_name":"Selank","claim":"Registered as a prescription anxiolytic in Russia; not approved by the FDA or EMA.","tier":1,"kind":"regulatory","source_label":"Zozulia et al., 2008 (Selank in GAD, PubMed)","source_url":"https://pubmed.ncbi.nlm.nih.gov/18454096/","updated":"2026-10-01","page":"https://peptides.info/peptides/selank"},{"peptide":"semax","peptide_name":"Semax","claim":"Regulated BDNF and TrkB expression in rat hippocampus – the mechanistic basis for its nootropic claims.","tier":3,"kind":"efficacy","source_label":"Dolotov et al., 2006 (Neuroscience)","source_url":"https://pubmed.ncbi.nlm.nih.gov/16996037/","updated":"2026-10-01","page":"https://peptides.info/peptides/semax"},{"peptide":"semax","peptide_name":"Semax","claim":"Neuroprotective and pro-cognitive effects reported in Russian clinical studies; not independently replicated in Western RCTs.","tier":4,"kind":"efficacy","source_label":"Gusev et al., 2018 (Zh Nevrol Psikhiatr)","source_url":"https://pubmed.ncbi.nlm.nih.gov/29798983/","updated":"2026-10-01","page":"https://peptides.info/peptides/semax"},{"peptide":"semax","peptide_name":"Semax","claim":"Registered in Russia as an intranasal drug; not approved by the FDA or EMA.","tier":1,"kind":"regulatory","source_label":"Dolotov et al., 2006 (Neuroscience)","source_url":"https://pubmed.ncbi.nlm.nih.gov/16996037/","updated":"2026-10-01","page":"https://peptides.info/peptides/semax"},{"peptide":"thymosin-alpha-1","peptide_name":"Thymosin alpha-1","claim":"Studied in chronic viral hepatitis, alone and combined with interferon.","tier":2,"kind":"efficacy","source_label":"Naylor, 1999 (Expert Opin Investig Drugs)","source_url":"https://pubmed.ncbi.nlm.nih.gov/15992078/","updated":"2026-09-19","page":"https://peptides.info/peptides/thymosin-alpha-1"},{"peptide":"thymosin-alpha-1","peptide_name":"Thymosin alpha-1","claim":"Improved immune measures and 28-day outcomes in severe sepsis in a multicenter randomized trial (ETASS).","tier":2,"kind":"efficacy","source_label":"Wu et al., 2013 (ETASS, Critical Care)","source_url":"https://pubmed.ncbi.nlm.nih.gov/23327199/","updated":"2026-09-19","page":"https://peptides.info/peptides/thymosin-alpha-1"},{"peptide":"bremelanotide","peptide_name":"Bremelanotide","claim":"FDA-approved for HSDD in premenopausal women, based on two Phase 3 trials (RECONNECT).","tier":1,"kind":"efficacy","source_label":"FDA label – Vyleesi (accessdata)","source_url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf","updated":"2026-09-19","page":"https://peptides.info/peptides/bremelanotide"},{"peptide":"bremelanotide","peptide_name":"Bremelanotide","claim":"Acts centrally as a melanocortin (MC4R/MC3R) agonist rather than on vascular blood flow.","tier":1,"kind":"efficacy","source_label":"FDA label – Vyleesi (accessdata)","source_url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf","updated":"2026-09-19","page":"https://peptides.info/peptides/bremelanotide"},{"peptide":"melanotan-ii","peptide_name":"Melanotan II","claim":"A broad-spectrum α-MSH analog and potent agonist at MC1R/MC3R/MC4R, driving pigmentation and sexual response (early human Phase I).","tier":2,"kind":"efficacy","source_label":"Dorr et al., 1996 (Life Sci, Phase I)","source_url":"https://pubmed.ncbi.nlm.nih.gov/8637402/","updated":"2026-09-19","page":"https://peptides.info/peptides/melanotan-ii"},{"peptide":"melanotan-ii","peptide_name":"Melanotan II","claim":"Systemic toxicity including rhabdomyolysis and renal dysfunction has been reported after injection.","tier":2,"kind":"efficacy","source_label":"Case report: MT-II toxicity and rhabdomyolysis (PubMed)","source_url":"https://pubmed.ncbi.nlm.nih.gov/23121206/","updated":"2026-09-19","page":"https://peptides.info/peptides/melanotan-ii"},{"peptide":"melanotan-ii","peptide_name":"Melanotan II","claim":"No approved human indication in any jurisdiction.","tier":1,"kind":"regulatory","source_label":"Dorr et al., 1996 (Life Sci, Phase I)","source_url":"https://pubmed.ncbi.nlm.nih.gov/8637402/","updated":"2026-09-19","page":"https://peptides.info/peptides/melanotan-ii"},{"peptide":"liraglutide","peptide_name":"Liraglutide","claim":"Produced 8.0% mean body-weight loss vs 2.6% on placebo over 56 weeks in adults without diabetes (SCALE).","tier":1,"kind":"efficacy","source_label":"Pi-Sunyer et al., 2015 (NEJM, SCALE)","source_url":"https://pubmed.ncbi.nlm.nih.gov/26132939/","updated":"2026-10-01","page":"https://peptides.info/peptides/liraglutide"},{"peptide":"liraglutide","peptide_name":"Liraglutide","claim":"Reduced major adverse cardiovascular events (hazard ratio 0.87) in type 2 diabetes at high cardiovascular risk (LEADER).","tier":1,"kind":"efficacy","source_label":"Marso et al., 2016 (NEJM, LEADER)","source_url":"https://pubmed.ncbi.nlm.nih.gov/27295427/","updated":"2026-10-01","page":"https://peptides.info/peptides/liraglutide"},{"peptide":"liraglutide","peptide_name":"Liraglutide","claim":"FDA-approved for type 2 diabetes and for chronic weight management.","tier":1,"kind":"regulatory","source_label":"FDA label – Saxenda (accessdata)","source_url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206321Orig1s000lbl.pdf","updated":"2026-10-01","page":"https://peptides.info/peptides/liraglutide"},{"peptide":"cagrilintide","peptide_name":"Cagrilintide","claim":"Produced 6.0% to 10.8% mean weight loss across doses vs 3.0% on placebo over 26 weeks, and beat liraglutide at the top dose (Phase 2).","tier":2,"kind":"efficacy","source_label":"Lau et al., 2021 (Lancet, Phase 2)","source_url":"https://pubmed.ncbi.nlm.nih.gov/34798060/","updated":"2026-10-01","page":"https://peptides.info/peptides/cagrilintide"},{"peptide":"cagrilintide","peptide_name":"Cagrilintide","claim":"Combined with semaglutide (CagriSema), produced 20.4% mean weight loss vs 3.0% on placebo at 68 weeks in a Phase 3 trial of 3,417 adults.","tier":2,"kind":"efficacy","source_label":"Garvey et al., 2025 (NEJM, REDEFINE 1)","source_url":"https://pubmed.ncbi.nlm.nih.gov/40544433/","updated":"2026-10-01","page":"https://peptides.info/peptides/cagrilintide"},{"peptide":"cagrilintide","peptide_name":"Cagrilintide","claim":"No approved indication in any jurisdiction.","tier":1,"kind":"regulatory","source_label":"Garvey et al., 2025 (NEJM, REDEFINE 1)","source_url":"https://pubmed.ncbi.nlm.nih.gov/40544433/","updated":"2026-10-01","page":"https://peptides.info/peptides/cagrilintide"},{"peptide":"sermorelin","peptide_name":"Sermorelin","claim":"Increased height velocity over 12 months in prepubertal children with idiopathic GH deficiency, with limited data suggesting the effect persists to 36 months.","tier":2,"kind":"efficacy","source_label":"Prakash & Goa, 1999 (BioDrugs review)","source_url":"https://pubmed.ncbi.nlm.nih.gov/18031173/","updated":"2026-10-01","page":"https://peptides.info/peptides/sermorelin"},{"peptide":"sermorelin","peptide_name":"Sermorelin","claim":"Produces a rapid, relatively specific GH response used diagnostically for GH deficiency.","tier":2,"kind":"efficacy","source_label":"Prakash & Goa, 1999 (BioDrugs review)","source_url":"https://pubmed.ncbi.nlm.nih.gov/18031173/","updated":"2026-10-01","page":"https://peptides.info/peptides/sermorelin"},{"peptide":"sermorelin","peptide_name":"Sermorelin","claim":"Formerly FDA-approved (Geref) for pediatric GH deficiency; discontinued in 2008, no approved product today.","tier":1,"kind":"regulatory","source_label":"Prakash & Goa, 1999 (BioDrugs review)","source_url":"https://pubmed.ncbi.nlm.nih.gov/18031173/","updated":"2026-10-01","page":"https://peptides.info/peptides/sermorelin"},{"peptide":"ghrp-2","peptide_name":"GHRP-2","claim":"Produced GH responses in children equal to GHRH and synergistic with it; intranasal doses were effective and well tolerated.","tier":2,"kind":"efficacy","source_label":"Pihoker et al., 1995 (J Clin Endocrinol Metab)","source_url":"https://pubmed.ncbi.nlm.nih.gov/7559885/","updated":"2026-10-01","page":"https://peptides.info/peptides/ghrp-2"},{"peptide":"ghrp-2","peptide_name":"GHRP-2","claim":"As a stimulation test, produced higher peak GH than the insulin tolerance test with high sensitivity and specificity for severe adult GH deficiency.","tier":2,"kind":"efficacy","source_label":"Kinoshita et al., 2013 (Endocr J)","source_url":"https://pubmed.ncbi.nlm.nih.gov/23079545/","updated":"2026-10-01","page":"https://peptides.info/peptides/ghrp-2"},{"peptide":"ghrp-2","peptide_name":"GHRP-2","claim":"Used as a diagnostic agent in Japan; no approved therapeutic indication anywhere.","tier":1,"kind":"regulatory","source_label":"Kinoshita et al., 2013 (Endocr J)","source_url":"https://pubmed.ncbi.nlm.nih.gov/23079545/","updated":"2026-10-01","page":"https://peptides.info/peptides/ghrp-2"},{"peptide":"ghrp-6","peptide_name":"GHRP-6","claim":"Raised overnight GH, ACTH and cortisol and increased stage 2 sleep in healthy men (placebo-controlled).","tier":2,"kind":"efficacy","source_label":"Frieboes et al., 1995 (Neuroendocrinology)","source_url":"https://pubmed.ncbi.nlm.nih.gov/7617137/","updated":"2026-10-01","page":"https://peptides.info/peptides/ghrp-6"},{"peptide":"ghrp-6","peptide_name":"GHRP-6","claim":"Given orally to short-statured children, produced a GH response comparable to intravenous GHRH.","tier":2,"kind":"efficacy","source_label":"Bellone et al., 1995 (Eur J Endocrinol)","source_url":"https://pubmed.ncbi.nlm.nih.gov/7581965/","updated":"2026-10-01","page":"https://peptides.info/peptides/ghrp-6"},{"peptide":"ghrp-6","peptide_name":"GHRP-6","claim":"Acts at the ghrelin receptor; its discovery led to the identification of GHS-R and of ghrelin itself.","tier":3,"kind":"efficacy","source_label":"Bowers, 2001 (J Clin Endocrinol Metab review)","source_url":"https://pubmed.ncbi.nlm.nih.gov/11297568/","updated":"2026-10-01","page":"https://peptides.info/peptides/ghrp-6"},{"peptide":"hexarelin","peptide_name":"Hexarelin","claim":"Two or three daily injections raised 24-hour GH secretion in healthy men without changing IGF-1, prolactin, ACTH or cortisol over one day.","tier":2,"kind":"efficacy","source_label":"Maccario et al., 2002 (Eur J Endocrinol)","source_url":"https://pubmed.ncbi.nlm.nih.gov/11888836/","updated":"2026-10-01","page":"https://peptides.info/peptides/hexarelin"},{"peptide":"hexarelin","peptide_name":"Hexarelin","claim":"Produced higher peak GH than insulin-induced hypoglycemia as a test of pituitary reserve in patients with pituitary disease.","tier":2,"kind":"efficacy","source_label":"Korbonits et al., 1999 (Clin Endocrinol)","source_url":"https://pubmed.ncbi.nlm.nih.gov/10469018/","updated":"2026-10-01","page":"https://peptides.info/peptides/hexarelin"},{"peptide":"hexarelin","peptide_name":"Hexarelin","claim":"Protected isolated rat hearts from calcium-paradox damage, an effect GH itself did not reproduce.","tier":3,"kind":"efficacy","source_label":"Torsello et al., 2001 (Endocrine)","source_url":"https://pubmed.ncbi.nlm.nih.gov/11322492/","updated":"2026-10-01","page":"https://peptides.info/peptides/hexarelin"},{"peptide":"afamelanotide","peptide_name":"Afamelanotide","claim":"Increased pain-free sunlight exposure and reduced phototoxic reactions versus placebo in two randomized trials in erythropoietic protoporphyria.","tier":1,"kind":"efficacy","source_label":"Langendonk et al., 2015 (NEJM)","source_url":"https://pubmed.ncbi.nlm.nih.gov/26132941/","updated":"2026-10-01","page":"https://peptides.info/peptides/afamelanotide"},{"peptide":"afamelanotide","peptide_name":"Afamelanotide","claim":"FDA-approved for erythropoietic protoporphyria in adults.","tier":1,"kind":"regulatory","source_label":"FDA label – Scenesse (accessdata)","source_url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf","updated":"2026-10-01","page":"https://peptides.info/peptides/afamelanotide"},{"peptide":"ll-37","peptide_name":"LL-37","claim":"Did not improve healing of hard-to-heal venous leg ulcers versus placebo in the full population of a Phase 2b RCT; a post-hoc subgroup with large wounds improved.","tier":2,"kind":"efficacy","source_label":"Mahlapuu et al., 2021 (Wound Repair Regen, Phase 2b)","source_url":"https://pubmed.ncbi.nlm.nih.gov/34687253/","updated":"2026-10-01","page":"https://peptides.info/peptides/ll-37"},{"peptide":"ll-37","peptide_name":"LL-37","claim":"Increased granulation tissue in mildly infected diabetic foot ulcers versus placebo cream in a small double-blind RCT.","tier":2,"kind":"efficacy","source_label":"Miranda et al., 2023 (Arch Dermatol Res)","source_url":"https://pubmed.ncbi.nlm.nih.gov/37480520/","updated":"2026-10-01","page":"https://peptides.info/peptides/ll-37"},{"peptide":"ll-37","peptide_name":"LL-37","claim":"Kills bacteria by membrane disruption and acts as a chemoattractant and angiogenic signal in vitro and in animals.","tier":3,"kind":"efficacy","source_label":"Dürr et al., 2006 (Biochim Biophys Acta review)","source_url":"https://pubmed.ncbi.nlm.nih.gov/16716248/","updated":"2026-10-01","page":"https://peptides.info/peptides/ll-37"},{"peptide":"thymosin-beta-4","peptide_name":"Thymosin β4","claim":"Missed both primary endpoints (discomfort, inferior corneal staining) but improved several secondary measures in a 72-patient placebo-controlled Phase 2 dry-eye trial.","tier":2,"kind":"efficacy","source_label":"Sosne & Ousler, 2015 (Clin Ophthalmol, Phase 2)","source_url":"https://pubmed.ncbi.nlm.nih.gov/26056426/","updated":"2026-10-01","page":"https://peptides.info/peptides/thymosin-beta-4"},{"peptide":"thymosin-beta-4","peptide_name":"Thymosin β4","claim":"Promotes cell migration, angiogenesis and wound repair and reduces scarring in animal models of skin, eye, heart and brain injury.","tier":3,"kind":"efficacy","source_label":"Goldstein et al., 2012 (Expert Opin Biol Ther)","source_url":"https://pubmed.ncbi.nlm.nih.gov/22074294/","updated":"2026-10-01","page":"https://peptides.info/peptides/thymosin-beta-4"},{"peptide":"thymosin-beta-4","peptide_name":"Thymosin β4","claim":"Phase 3 trials in dry eye and neurotrophic keratopathy are ongoing; no result has been published at review.","tier":4,"kind":"efficacy","source_label":"Sosne, 2018 (Expert Opin Biol Ther)","source_url":"https://pubmed.ncbi.nlm.nih.gov/30063853/","updated":"2026-10-01","page":"https://peptides.info/peptides/thymosin-beta-4"},{"peptide":"dihexa","peptide_name":"Dihexa","claim":"Reversed scopolamine-induced memory deficits and increased hippocampal synaptogenesis in rats (study now under a Notice of Concern).","tier":3,"kind":"efficacy","source_label":"McCoy et al., 2013 (J Pharmacol Exp Ther)","source_url":"https://pubmed.ncbi.nlm.nih.gov/23055539/","updated":"2026-10-01","page":"https://peptides.info/peptides/dihexa"},{"peptide":"dihexa","peptide_name":"Dihexa","claim":"Restored spatial learning and reduced neuroinflammation in APP/PS1 Alzheimer's-model mice via PI3K/AKT signalling (independent group).","tier":3,"kind":"efficacy","source_label":"Sun et al., 2021 (Brain Sci)","source_url":"https://pubmed.ncbi.nlm.nih.gov/34827486/","updated":"2026-10-01","page":"https://peptides.info/peptides/dihexa"},{"peptide":"dihexa","peptide_name":"Dihexa","claim":"The claim that its effects depend on HGF/c-Met activation rests on a paper retracted in 2025.","tier":4,"kind":"efficacy","source_label":"Benoist et al., 2014 – retraction notice (J Pharmacol Exp Ther)","source_url":"https://pubmed.ncbi.nlm.nih.gov/40312093/","updated":"2026-10-01","page":"https://peptides.info/peptides/dihexa"}]}